Progress of hearing loss in neurofibromatosis type 2: implications for future management

被引:18
|
作者
Kontorinis, Georgios [1 ,2 ]
Nichani, Jaya [1 ]
Freeman, Simon R. [1 ]
Rutherford, Scott A. [3 ]
Mills, Samantha [4 ]
King, Andrew T. [3 ]
Mawman, Deborah [1 ]
Huson, Sue [5 ]
O'Driscoll, Martin [1 ]
Gareth Evans, D. [5 ]
Lloyd, Simon K. W. [1 ,6 ,7 ]
机构
[1] Cent Manchester Univ Hosp, NHS Fdn Trust, Univ Dept Otolaryngol, Manchester M13 9PL, Lancs, England
[2] Southern Teaching Hosp, Inst Neurosci, Dept Otolaryngol, Glasgow, Lanark, Scotland
[3] Salford Royal NHS Fdn Trust, Dept Neurosurg, Manchester, Lancs, England
[4] Salford Royal NHS Fdn Trust, Dept Neuroradiol, Manchester, Lancs, England
[5] Cent Manchester Univ Hosp, NHS Fdn Trust, Dept Med Genet, Manchester M13 9PL, Lancs, England
[6] Univ Manchester, Sch Canc, Manchester M13 9PL, Lancs, England
[7] Univ Manchester, Enabling Serv, Manchester M13 9PL, Lancs, England
关键词
Conservative treatment; Deafness; Neurofibromatosis type 2; Tumour size; Vestibular schwannoma; Watch wait rescan protocol; VESTIBULAR SCHWANNOMAS; NATURAL-HISTORY; CONSERVATIVE MANAGEMENT; COCHLEAR IMPLANTATION; UNITED-KINGDOM; GROWTH; PRESERVATION; NF2;
D O I
10.1007/s00405-014-3317-7
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
The objective of this study was to describe changes in hearing over time in patients with neurofibromatosis type 2 (NF2) treated conservatively. A retrospective case review was conducted in a tertiary referral centre. Pure tone audiometry, speech discrimination scores, serviceable hearing (American Academy of Otolaryngology class A or B) and measurement of vestibular schwannoma (VS) size on magnetic resonance imaging were evaluated in 56 patients (89 ears) with NF2 with at least one conservatively managed VS. Over a mean follow-up period of 7 years (range 0.8-21 years) pure tone average thresholds increased gradually with a mean annual rate of 1.3 dB for the right ear (p = 0.0003) and 2 dB for the left ear (p = 0.0009). Speech discrimination scores dropped with an average annual rate of 1.3 and 0.34 % in the right and left ear, respectively. Patients maintained serviceable hearing for an average of 7.6 years (range 2.7-19.3 years). The average annual VS growth was 0.4 mm without any correlation with hearing loss. There was a correlation between patients' age and pure tone threshold increase (p < 0.05 for both ears). In this selected population of patients with NF2, hearing threshold increases were very slow. In NF2 patients with indolently behaving tumours, serviceable hearing can be maintained for a significant length of time, making conservative management an attractive option.
引用
收藏
页码:3143 / 3150
页数:8
相关论文
共 50 条
  • [31] Pediatric unilateral sensorineural hearing loss: implications and management
    Dornhoffer, James R.
    Dornhoffer, John L.
    CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY, 2016, 24 (06): : 522 - 528
  • [32] Progress in the diagnosis and management of neurofibromatosis
    Korf, BR
    FAMILIAL CANCER AND PREVENTION: MOLECULAR EPIDEMIOLOGY - A NEW STRATEGY TOWARD CANCER CONTROL, 1999, : 455 - 459
  • [33] Options and strategies for hearing restoration in pediatric neurofibromatosis type 2
    Hossein Mahboubi
    William H. Slattery
    Gautam U. Mehta
    Gregory P. Lekovic
    Child's Nervous System, 2020, 36 : 2481 - 2487
  • [34] Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2
    Plotkin, Scott R.
    Stemmer-Rachamimov, Anat O.
    Barker, Fred G., II
    Halpin, Chris
    Padera, Timothy P.
    Tyrrell, Alex
    Sorensen, A. Gregory
    Jain, Rakesh K.
    di Tomaso, Emmanuelle
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (04): : 358 - 367
  • [35] Options and strategies for hearing restoration in pediatric neurofibromatosis type 2
    Mahboubi, Hossein
    Slattery, William H., III
    Mehta, Gautam U.
    Lekovic, Gregory P.
    CHILDS NERVOUS SYSTEM, 2020, 36 (10) : 2481 - 2487
  • [36] Type 2 diabetes and hearing loss
    Hong, OiSaeng
    Buss, Julia
    Thomas, Elizabeth
    DM DISEASE-A-MONTH, 2013, 59 (04): : 139 - 146
  • [37] Gene Therapy for Neurofibromatosis Type 2-Related Schwannomatosis: Recent Progress, Challenges, and Future Directions
    Yuan, Ruofei
    Wang, Bo
    Wang, Ying
    Liu, Pinan
    ONCOLOGY AND THERAPY, 2024, 12 (02) : 257 - 276
  • [38] Conservative Management of Bilateral Vestibular Schwannomas in Neurofibromatosis Type 2 Patients: Hearing and Tumor Growth Results
    Peyre, Matthieu
    Goutagny, Stephane
    Bah, Alpha
    Bernardeschi, Daniele
    Larroque, Beatrice
    Sterkers, Olivier
    Kalamarides, Michel
    NEUROSURGERY, 2013, 72 (06) : 907 - 913
  • [39] Incidence of Hearing Loss in Patients With Neurofibromatosis Type 1 at a Tertiary Care Pediatric Hospital
    Yun, Alice
    Grif, Amanda M.
    Kim, Hae-Young
    Ullrich, Nicole J.
    Licameli, Greg R.
    PEDIATRIC NEUROLOGY, 2024, 159 : 35 - 40
  • [40] NEUROFIBROMATOSIS TYPE-1 - A RARE CASE RESULTING IN CONDUCTIVE HEARING-LOSS
    MCKENNAN, KX
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 1991, 104 (06) : 868 - 872